We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals

26 hedge funds and large institutions have $1.6M invested in Armata Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

30% more funds holding

Funds holding: 2026 (+6)

0.15% less ownership

Funds ownership: 3.76%3.61% (-0.15%)

72% less capital invested

Capital invested by funds: $5.73M → $1.6M (-$4.13M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
26
Holders Change
+6
Holders Change %
+30%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
9
Reduced
3
Closed
3
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K
Name Holding Trade Value Shares
Change
Change in
Stake
SF
26
Synovus Financial
Georgia
-$202K -47,903 Closed
Osaic Holdings
27
Osaic Holdings
Arizona
-$23K -5,500 Closed
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
-$1K -134 Closed

ARMP Hedge Fund Activity: Q4 2022 in Review

26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2022, worth a combined $1.6M — down 72% from $5.73M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ARMP positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 3 trimmed.

The largest buyer was Bridgeway Capital Management, adding an estimated $208K. The largest seller was Vanguard Group, cutting an estimated $634K.

  • 26 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2022, up from 20 in Q3 2022.
  • Funds reported $1.6M of Armata Pharmaceuticals stock for Q4 2022, down 72% quarter-over-quarter.
  • 9 funds opened new Armata Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of +6 holders.
  • The largest Armata Pharmaceuticals buyer in Q4 2022 was Bridgeway Capital Management, an estimated $208K added.
  • The largest Armata Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $634K sold.

Based on aggregated 13F filings for Q4 2022.